Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akoya Biosciences, Inc.AKYA · Entity 77553 | Chief Financial Officer | December 22, 2022 | December 27, 2022 |
| Quanterix CorpQTRX · Entity 6649 | Chief Financial Officer | January 15, 2019 | January 15, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akoya Biosciences, Inc.
Report date December 22, 2022 · Filed December 27, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 262,500 |
Reported balance
After 2022-12-22 transaction · row 1
1 source rowRow 1 · 2022-12-22 · Exercise / conversion · Acquired 250,000 · Balance 262,500 |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.44 · Expires 2029-05-02 | Direct | 110,958 |
Reported balance
After 2022-12-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-12-22 · Exercise / conversion · Disposed 250,000 · Balance 110,958 F1: The option will be fully vested on 03/18/2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will be fully vested on 03/18/2023.
Quanterix Corp
Report date January 15, 2019 · Filed January 15, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,388 |
Last balance in matching sequence
After 2019-01-15 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2019-01-15 · Exercise / conversion · Acquired 15,000 · Balance 19,388 F1: Includes 4,388 shares of common stock issuable upon vesting of restricted stock units that vest as to 25% of the shares on May 10, 2019 and as to an additional 2.083% of the shares per month for 36 months thereafter. Row 2 · 2019-01-15 · Sale · Disposed 6,818 · Balance 12,570 F2: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2018. F3: This transaction was executed in multiple trades at prices ranging from $19.54 USD to $20.50. The price reported above reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1: Includes 4,388 shares of common stock issuable upon vesting of restricted stock units that vest as to 25% of the shares on May 10, 2019 and as to an additional 2.083% of the shares per month for 36 months thereafter. Row 3 · 2019-01-15 · Sale · Disposed 7,831 · Balance 4,739 F2: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2018. F4: This transaction was executed in multiple trades at prices ranging from $20.57 USD to $21.49. The price reported above reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1: Includes 4,388 shares of common stock issuable upon vesting of restricted stock units that vest as to 25% of the shares on May 10, 2019 and as to an additional 2.083% of the shares per month for 36 months thereafter. Row 4 · 2019-01-15 · Sale · Disposed 351 · Balance 4,388 F2: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2018. F5: This transaction was executed in multiple trades at prices ranging from $21.68 USD to $21.70. The price reported above reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1: Includes 4,388 shares of common stock issuable upon vesting of restricted stock units that vest as to 25% of the shares on May 10, 2019 and as to an additional 2.083% of the shares per month for 36 months thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.68 · Expires 2027-06-02 | Direct | 199,385 |
Reported balance
After 2019-01-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-01-15 · Exercise / conversion · Disposed 15,000 · Balance 199,385 F6: This option to purchase 301,722 shares of common stock vested as to 25% of the shares on April 24, 2018 and vests as to an additional 2.083% of the shares per month thereafter until March 31, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 4,388 shares of common stock issuable upon vesting of restricted stock units that vest as to 25% of the shares on May 10, 2019 and as to an additional 2.083% of the shares per month for 36 months thereafter.
F2: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2018.
F3: This transaction was executed in multiple trades at prices ranging from $19.54 USD to $20.50. The price reported above reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This transaction was executed in multiple trades at prices ranging from $20.57 USD to $21.49. The price reported above reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: This transaction was executed in multiple trades at prices ranging from $21.68 USD to $21.70. The price reported above reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6: This option to purchase 301,722 shares of common stock vested as to 25% of the shares on April 24, 2018 and vests as to an additional 2.083% of the shares per month thereafter until March 31, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 22, 2022 Filed Dec 27, 2022 16:05 UTC | Akoya Biosciences, Inc. AKYA · Entity 77553 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0001104659-22-130165 · tm2233541-1_4seq1.xml · derivative · entry 2 DRISCOLL JOSEPH · CIK 0001392297 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,958 Underlying: Common Stock · 250,000 shares Expires 2029-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option will be fully vested on 03/18/2023. Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 16:05 UTC | Akoya Biosciences, Inc. AKYA · Entity 77553 | Exercise / conversionCommon Stock | 250,000 | $0.44 | $110,000.00 |
DisclosureSEC source: 0001104659-22-130165 · tm2233541-1_4seq1.xml · nonDerivative · entry 1 DRISCOLL JOSEPH · CIK 0001392297 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 17:59 UTC | Akoya Biosciences, Inc. AKYA · Entity 77553 | Exercise / conversionEmployee Stock Option (Right to Buy · Derivative | 14,574 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0001104659-22-127961 · tm2232955-1_4seq1.xml · derivative · entry 6 DRISCOLL JOSEPH · CIK 0001392297 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,712 Underlying: Common Stock · 14,574 shares Expires 2029-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Such performance-based option shares were issued in 2019. In 2020, the options vested as performance conditions were determined to have been achieved. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 17:59 UTC | Akoya Biosciences, Inc. AKYA · Entity 77553 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,039 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0001104659-22-127961 · tm2232955-1_4seq1.xml · derivative · entry 5 DRISCOLL JOSEPH · CIK 0001392297 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,466 Underlying: Common Stock · 10,039 shares Expires 2029-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Such performance-based option shares were issued in 2019. In 2020, the options vested as performance conditions were determined to have been achieved. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 17:59 UTC | Akoya Biosciences, Inc. AKYA · Entity 77553 | SaleCommon Stock | 14,574 | $12.46 | $181,519.17 |
DisclosureSEC source: 0001104659-22-127961 · tm2232955-1_4seq1.xml · nonDerivative · entry 4 DRISCOLL JOSEPH · CIK 0001392297 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 F2 · price: Column 4 reflects a weighted average price. Shares sold in multiple transactions at prices ranging from $12.40 - $12.615. Reporting person undertakes to provide issuer, securityholder of issuer or SEC staff, upon request, information regarding number of shares sold at each separate price within ranges set forth herein. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 17:59 UTC | Akoya Biosciences, Inc. AKYA · Entity 77553 | Exercise / conversionCommon Stock | 14,574 | $0.44 | $6,412.56 |
DisclosureSEC source: 0001104659-22-127961 · tm2232955-1_4seq1.xml · nonDerivative · entry 3 DRISCOLL JOSEPH · CIK 0001392297 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 17:59 UTC | Akoya Biosciences, Inc. AKYA · Entity 77553 | SaleCommon Stock | 10,039 | $12.67 | $127,187.10 |
DisclosureSEC source: 0001104659-22-127961 · tm2232955-1_4seq1.xml · nonDerivative · entry 2 DRISCOLL JOSEPH · CIK 0001392297 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 F1 · price: Column 4 reflects a weighted average price. Shares sold in multiple transactions at prices ranging from $12.60 - $12.80. Reporting person undertakes to provide issuer, securityholder of issuer or SEC staff, upon request, information regarding number of shares sold at each separate price within ranges set forth herein. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 17:59 UTC | Akoya Biosciences, Inc. AKYA · Entity 77553 | Exercise / conversionCommon Stock | 10,039 | $0.44 | $4,417.16 |
DisclosureSEC source: 0001104659-22-127961 · tm2232955-1_4seq1.xml · nonDerivative · entry 1 DRISCOLL JOSEPH · CIK 0001392297 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,539 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 23, 2022 Filed Mar 25, 2022 19:23 UTC | Akoya Biosciences, Inc. AKYA · Entity 77553 | GrantEmployee Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $11.88 | $0.00 |
DisclosureSEC source: 0001104659-22-038232 · tm2210432-2_4seq1.xml · derivative · entry 2 DRISCOLL JOSEPH · CIK 0001392297 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-03-23 F3 · derivative.exercise_date: The options shall vest as follows: twenty-five percent (25%) shall vest on the first anniversary of the grant date with the remainder vesting in 36 equal monthly installments beginning on April 23, 2023. Read SEC document |
| March 23, 2022 Filed Mar 25, 2022 19:23 UTC | Akoya Biosciences, Inc. AKYA · Entity 77553 | GrantCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-038232 · tm2210432-2_4seq1.xml · nonDerivative · entry 1 DRISCOLL JOSEPH · CIK 0001392297 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 F1 · shares: The restricted stock units shall vest in four (4) equal annual installments beginning on the first anniversary of the grant date and on each anniversary thereafter. F2 · price: Each restricted stock unit represents a contingent right to receive one share of Akoya Biosciences, Inc. common stock. Read SEC document |
| January 15, 2019 Filed Jan 15, 2019 16:02 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $8.68 | $0.00 |
DisclosureSEC source: 0001562180-19-000307 · primarydocument.xml · derivative · entry 5 DRISCOLL JOSEPH · CIK 0001392297 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,385 Underlying: Common Stock · 15,000 shares Expires 2027-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option to purchase 301,722 shares of common stock vested as to 25% of the shares on April 24, 2018 and vests as to an additional 2.083% of the shares per month thereafter until March 31, 2021. Read SEC document |
| January 15, 2019 Filed Jan 15, 2019 16:02 UTC | Quanterix Corp QTRX · Entity 6649 | SaleCommon Stock | 351 | $21.69 | $7,613.68 |
DisclosureSEC source: 0001562180-19-000307 · primarydocument.xml · nonDerivative · entry 4 DRISCOLL JOSEPH · CIK 0001392297 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,388 F2 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2018. F5 · price: This transaction was executed in multiple trades at prices ranging from $21.68 USD to $21.70. The price reported above reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: Includes 4,388 shares of common stock issuable upon vesting of restricted stock units that vest as to 25% of the shares on May 10, 2019 and as to an additional 2.083% of the shares per month for 36 months thereafter. Read SEC document |
| January 15, 2019 Filed Jan 15, 2019 16:02 UTC | Quanterix Corp QTRX · Entity 6649 | SaleCommon Stock | 7,831 | $20.93 | $163,934.15 |
DisclosureSEC source: 0001562180-19-000307 · primarydocument.xml · nonDerivative · entry 3 DRISCOLL JOSEPH · CIK 0001392297 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,739 F2 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2018. F4 · price: This transaction was executed in multiple trades at prices ranging from $20.57 USD to $21.49. The price reported above reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: Includes 4,388 shares of common stock issuable upon vesting of restricted stock units that vest as to 25% of the shares on May 10, 2019 and as to an additional 2.083% of the shares per month for 36 months thereafter. Read SEC document |
| January 15, 2019 Filed Jan 15, 2019 16:02 UTC | Quanterix Corp QTRX · Entity 6649 | SaleCommon Stock | 6,818 | $19.97 | $136,133.64 |
DisclosureSEC source: 0001562180-19-000307 · primarydocument.xml · nonDerivative · entry 2 DRISCOLL JOSEPH · CIK 0001392297 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,570 F2 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2018. F3 · price: This transaction was executed in multiple trades at prices ranging from $19.54 USD to $20.50. The price reported above reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: Includes 4,388 shares of common stock issuable upon vesting of restricted stock units that vest as to 25% of the shares on May 10, 2019 and as to an additional 2.083% of the shares per month for 36 months thereafter. Read SEC document |
| January 15, 2019 Filed Jan 15, 2019 16:02 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionCommon Stock | 15,000 | $8.68 | $130,200.00 |
DisclosureSEC source: 0001562180-19-000307 · primarydocument.xml · nonDerivative · entry 1 DRISCOLL JOSEPH · CIK 0001392297 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,388 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 4,388 shares of common stock issuable upon vesting of restricted stock units that vest as to 25% of the shares on May 10, 2019 and as to an additional 2.083% of the shares per month for 36 months thereafter. Read SEC document |
| December 13, 2018 Filed Dec 14, 2018 16:14 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $8.68 | $0.00 |
DisclosureSEC source: 0001562180-18-004949 · primarydocument.xml · derivative · entry 4 DRISCOLL JOSEPH · CIK 0001392297 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,385 Underlying: Common Stock · 20,000 shares Expires 2027-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option to purchase 301,722 shares of common stock vested as to 25% of the shares on April 24, 2018 and vests as to an additional 2.083% of the shares per month thereafter until March 31, 2021. Read SEC document |
| December 13, 2018 Filed Dec 14, 2018 16:14 UTC | Quanterix Corp QTRX · Entity 6649 | SaleCommon Stock | 601 | $20.02 | $12,031.06 |
DisclosureSEC source: 0001562180-18-004949 · primarydocument.xml · nonDerivative · entry 3 DRISCOLL JOSEPH · CIK 0001392297 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,388 F3 · price: This transaction was executed in multiple trades at prices ranging from $20.012 to $20.06. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: Includes 4,388 shares of common stock issuable upon vesting of restricted stock units that vest as to 25% of the shares on May 10, 2019 and as to an additional 2.083% of the shares per month for 36 months thereafter. Read SEC document |
| December 13, 2018 Filed Dec 14, 2018 16:14 UTC | Quanterix Corp QTRX · Entity 6649 | SaleCommon Stock | 19,399 | $19.19 | $372,183.39 |
DisclosureSEC source: 0001562180-18-004949 · primarydocument.xml · nonDerivative · entry 2 DRISCOLL JOSEPH · CIK 0001392297 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,989 F2 · price: This transaction was executed in multiple trades at prices ranging from $19.00 to $19.99. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: Includes 4,388 shares of common stock issuable upon vesting of restricted stock units that vest as to 25% of the shares on May 10, 2019 and as to an additional 2.083% of the shares per month for 36 months thereafter. Read SEC document |
| December 13, 2018 Filed Dec 14, 2018 16:14 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionCommon Stock | 20,000 | $8.68 | $173,600.00 |
DisclosureSEC source: 0001562180-18-004949 · primarydocument.xml · nonDerivative · entry 1 DRISCOLL JOSEPH · CIK 0001392297 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,388 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 4,388 shares of common stock issuable upon vesting of restricted stock units that vest as to 25% of the shares on May 10, 2019 and as to an additional 2.083% of the shares per month for 36 months thereafter. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 16:09 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $8.68 | $0.00 |
DisclosureSEC source: 0001562180-18-004848 · primarydocument.xml · derivative · entry 3 DRISCOLL JOSEPH · CIK 0001392297 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,385 Underlying: Common Stock · 20,000 shares Expires 2027-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option to purchase 301,722 shares of common stock vested as to 25% of the shares on April 24, 2018 and vests as to an additional 2.083% of the shares per month thereafter until March 31, 2021. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 16:09 UTC | Quanterix Corp QTRX · Entity 6649 | SaleCommon Stock | 20,000 | $18.47 | $369,354.00 |
DisclosureSEC source: 0001562180-18-004848 · primarydocument.xml · nonDerivative · entry 2 DRISCOLL JOSEPH · CIK 0001392297 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,388 F2 · price: This transaction was executed in multiple trades at prices ranging from $18.45 to $18.65. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: Includes 4,388 shares of common stock issuable upon vesting of restricted stock units that vest as to 25% of the shares on May 10, 2019 and as to an additional 2.083% of the shares per month for 36 months thereafter. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 16:09 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionCommon Stock | 20,000 | $8.68 | $173,600.00 |
DisclosureSEC source: 0001562180-18-004848 · primarydocument.xml · nonDerivative · entry 1 DRISCOLL JOSEPH · CIK 0001392297 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,388 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 4,388 shares of common stock issuable upon vesting of restricted stock units that vest as to 25% of the shares on May 10, 2019 and as to an additional 2.083% of the shares per month for 36 months thereafter. Read SEC document |
| November 28, 2018 Filed Nov 30, 2018 16:05 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $8.68 | $0.00 |
DisclosureSEC source: 0001562180-18-004754 · primarydocument.xml · derivative · entry 3 DRISCOLL JOSEPH · CIK 0001392297 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,385 Underlying: Common Stock · 20,000 shares Expires 2027-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option to purchase 301,722 shares of common stock vested as to 25% of the shares on April 24, 2018 and vests as to an additional 2.083% of the shares per month thereafter until March 31, 2021. Read SEC document |
| November 28, 2018 Filed Nov 30, 2018 16:05 UTC | Quanterix Corp QTRX · Entity 6649 | SaleCommon Stock | 20,000 | $17.80 | $356,050.00 |
DisclosureSEC source: 0001562180-18-004754 · primarydocument.xml · nonDerivative · entry 2 DRISCOLL JOSEPH · CIK 0001392297 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,388 F2 · price: This transaction was executed in multiple trades at prices ranging from $17.80 to $18.00. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: Includes 4,388 shares of common stock issuable upon vesting of restricted stock units that vest as to 25% of the shares on May 10, 2019 and as to an additional 2.083% of the shares per month for 36 months thereafter. Read SEC document |
| November 28, 2018 Filed Nov 30, 2018 16:05 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionCommon Stock | 20,000 | $8.68 | $173,600.00 |
DisclosureSEC source: 0001562180-18-004754 · primarydocument.xml · nonDerivative · entry 1 DRISCOLL JOSEPH · CIK 0001392297 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,388 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 4,388 shares of common stock issuable upon vesting of restricted stock units that vest as to 25% of the shares on May 10, 2019 and as to an additional 2.083% of the shares per month for 36 months thereafter. Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 16:11 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $8.68 | $0.00 |
DisclosureSEC source: 0001562180-18-004593 · primarydocument.xml · derivative · entry 3 DRISCOLL JOSEPH · CIK 0001392297 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,385 Underlying: Common Stock · 25,000 shares Expires 2027-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option to purchase 301,722 shares of common stock vested as to 25% of the shares on April 24, 2018 and vests as to an additional 2.083% of the shares per month thereafter until March 31, 2021. Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 16:11 UTC | Quanterix Corp QTRX · Entity 6649 | SaleCommon Stock | 25,000 | $16.60 | $415,000.00 |
DisclosureSEC source: 0001562180-18-004593 · primarydocument.xml · nonDerivative · entry 2 DRISCOLL JOSEPH · CIK 0001392297 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,388 F1 · balance_after: Includes 4,388 shares of common stock issuable upon vesting of restricted stock units that vest as to 25% of the shares on May 10, 2019 and as to an additional 2.083% of the shares per month for 36 months thereafter. Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 16:11 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionCommon Stock | 25,000 | $8.68 | $217,000.00 |
DisclosureSEC source: 0001562180-18-004593 · primarydocument.xml · nonDerivative · entry 1 DRISCOLL JOSEPH · CIK 0001392297 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,388 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 4,388 shares of common stock issuable upon vesting of restricted stock units that vest as to 25% of the shares on May 10, 2019 and as to an additional 2.083% of the shares per month for 36 months thereafter. Read SEC document |
| November 08, 2018 Filed Nov 13, 2018 16:30 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionStock Option (right to buy) · Derivative | 2,337 | $0.00 Strike: $8.68 | $0.00 |
DisclosureSEC source: 0001562180-18-004522 · primarydocument.xml · derivative · entry 3 DRISCOLL JOSEPH · CIK 0001392297 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,385 Underlying: Common Stock · 2,337 shares Expires 2027-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option to purchase 301,722 shares of common stock vested as to 25% of the shares on April 24, 2018 and vests as to an additional 2.083% of the shares per month thereafter until March 31, 2021. Read SEC document |
| November 08, 2018 Filed Nov 13, 2018 16:30 UTC | Quanterix Corp QTRX · Entity 6649 | SaleCommon Stock | 2,337 | $17.36 | $40,570.32 |
DisclosureSEC source: 0001562180-18-004522 · primarydocument.xml · nonDerivative · entry 2 DRISCOLL JOSEPH · CIK 0001392297 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,388 F2 · price: This transaction was executed in multiple trades at prices ranging from $17.30 to $17.40. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: Includes 4,388 shares of common stock issuable upon vesting of restricted stock units that vest as to 25% of the shares on May 10, 2019 and as to an additional 2.083% of the shares per month for 36 months thereafter. Read SEC document |
| November 08, 2018 Filed Nov 13, 2018 16:30 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionCommon Stock | 2,337 | $8.68 | $20,285.16 |
DisclosureSEC source: 0001562180-18-004522 · primarydocument.xml · nonDerivative · entry 1 DRISCOLL JOSEPH · CIK 0001392297 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 4,388 shares of common stock issuable upon vesting of restricted stock units that vest as to 25% of the shares on May 10, 2019 and as to an additional 2.083% of the shares per month for 36 months thereafter. Read SEC document |
| May 10, 2018 Filed May 14, 2018 21:00 UTC | Quanterix Corp QTRX · Entity 6649 | GrantStock Option (right to buy) · Derivative | 14,960 | $0.00 Strike: $19.12 | $0.00 |
DisclosureSEC source: 0001104659-18-033073 · a4.xml · derivative · entry 2 DRISCOLL JOSEPH · CIK 0001392297 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,960 Underlying: Common Stock · 14,960 shares Expires 2028-05-10 F3 · derivative.exercise_date: The option vests as to 25% of the shares on May 10, 2019 and vests as to an additional 2.083% of the shares per month for 36 months thereafter. Read SEC document |
| May 10, 2018 Filed May 14, 2018 21:00 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 4,388 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-033073 · a4.xml · nonDerivative · entry 1 DRISCOLL JOSEPH · CIK 0001392297 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,388 F1 · shares: Represents shares of common stock issuable upon vesting of restricted stock units. The restricted stock units vest as to 25% of the shares on May 10, 2019 and vest as to an additional 2.083% of the shares per month for 36 months thereafter. F2 · balance_after: Represents 4,388 restricted stock units. Read SEC document |
| August 31, 2017 Filed Dec 13, 2017 16:23 UTC | Quanterix Corp QTRX · Entity 6649 | GrantStock Option (right to buy) · Derivative | 10,976 | $0.00 Strike: $9.42 | $0.00 |
DisclosureSEC source: 0001104659-17-073150 · a4.xml · derivative · entry 1 DRISCOLL JOSEPH · CIK 0001392297 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,976 Underlying: Common Stock · 10,976 shares Expires 2027-08-31 F1 · security: This transaction, which occurred prior to the Issuer's initial public offering of common stock, is being reported as required by Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. F2 · derivative.exercise_price: Reflects the 1-for-3.214 reverse stock split of the Issuer's common stock effected on December 4, 2017 in connection with the Issuer's initial public offering, pursuant to which (i) the number of shares of common stock underlying the option was divided by 3.214 and (ii) the exercise price of the option was multiplied by 3.214. F2 · shares: Reflects the 1-for-3.214 reverse stock split of the Issuer's common stock effected on December 4, 2017 in connection with the Issuer's initial public offering, pursuant to which (i) the number of shares of common stock underlying the option was divided by 3.214 and (ii) the exercise price of the option was multiplied by 3.214. F3 · derivative.exercise_date: The option vests as to 25% of the shares on April 24, 2018 and vests as to an additional 2.083% of the shares per month thereafter until March 31, 2021. F2 · derivative.underlying_shares: Reflects the 1-for-3.214 reverse stock split of the Issuer's common stock effected on December 4, 2017 in connection with the Issuer's initial public offering, pursuant to which (i) the number of shares of common stock underlying the option was divided by 3.214 and (ii) the exercise price of the option was multiplied by 3.214. F2 · balance_after: Reflects the 1-for-3.214 reverse stock split of the Issuer's common stock effected on December 4, 2017 in connection with the Issuer's initial public offering, pursuant to which (i) the number of shares of common stock underlying the option was divided by 3.214 and (ii) the exercise price of the option was multiplied by 3.214. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.